Unknown PHASE2 INTERVENTIONAL 2-arm NCT00797472

Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease

A Phase II Open Label, Multicenter, Randomized, Parallel Study Comparing the Efficacy of R-mabHD Alone and a Combination of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD)in Treating Patients With Hodgkin's Disease.

Sponsor: American Scitech International

Conditions Hodgkin's Disease

Interventions ABVD R-mabHD

Updated 7 times since 2017 Last updated: Jul 19, 2011 Started: Jul 31, 2011 Primary completion: Apr 30, 2014 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hodgkin's Disease and is currently ongoing. American Scitech International leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Nov 2019 — Jan 2021 [monthly]

Unknown Status PHASE2
Jun 2018 — Nov 2019 [monthly]

Unknown Status PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

American Scitech International
Bristol-Myers Squibb
Eli Lilly and Company

Data source: American Scitech International

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Englishtown, United States